Clay Siegall, Seattle Genetics president & CEO, discusses his company's latest drug developments for non-hodgkins lymphoma and hodgkins lymphoma, and its opportunity to be a "$1 billion plus product on its own."
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT